Screening is planned to begin in April 2026, with enrolment completion expected by the end of the first quarter of 2027.

The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.

Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.--(BUSINESS ...

Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.

Aligos Therapeutics Inc. (NASDAQ:ALGS) shares surged 20% on Thursday after the company announced an exclusive licensing deal ...

Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high ...

Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

Researchers have achieved a 4.4 Å cryo-electron microscopy reconstruction of the giant Melbournevirus capsid, with a ...

Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size ...

Researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology—an emerging technology that uses ...

U.S. Supreme Court opinions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., Association for Molecular Pathology v. Myriad ...